论文部分内容阅读
在浸润性膀胱癌的治疗中,术前放疗的作用是有争议的,为弄清术前放疗的作用,作者复习了1980～1982年行膀胱切除术的58例膀胱移行细胞癌。58例患者均被随访3年以上。36例于术前放疗(RT)后行膀胱切除(C),22例仅行C。放疗剂量为1000～4000rad,3天至4周内给予,其中18例放射量达4000tad。结果两组病理分期相似,RT+C组较C组稍好,B_2期以上者分别为55％和68％;两组肿瘤分级相似,2/3的肿瘤为3或4级。 RT+C组的1,2,3年无癌生存率分别为86％、76％和60％;而C组为94％、80％和70％。
In the treatment of invasive bladder cancer, the role of preoperative radiotherapy is controversial. To clarify the role of preoperative radiotherapy, the author reviewed 58 cases of bladder transitional cell carcinoma who underwent cystectomy from 1980 to 1982. All 58 patients were followed up for more than 3 years. Thirty-six patients underwent cystectomy (C) after preoperative radiotherapy (RT), and 22 patients only received C. Radiotherapy doses ranged from 1000 to 4000 rad. They were given within 3 days to 4 weeks, of which 18 cases had a radiation dose of 4000 tad. Results The pathological stages of the two groups were similar. The RT+C group was slightly better than the C group. The patients above the B2 stage were 55% and 68% respectively. The tumor grades of the two groups were similar, and 2/3 of the tumors were grade 3 or 4. The 1-, 2-, and 3-year cancer-free survival rates were 86%, 76%, and 60% in the RT+C group, and 94%, 80%, and 70% in the C group.